Coral raises $12.5M to automate healthcare’s administrative back office


The New York startup has built AI that reads handwritten fax forms, processes prior authorisations, and completes patient intakes in under five minutes, all without asking providers to change how they work. It has reached multiple millions in revenue in under a year and is targeting 4x growth by end of 2026.


Coral, the New York-based AI startup automating administrative workflows for specialty healthcare providers, has raised $12.5 million in a Series A led by Lightspeed and Z47.

The company was founded in 2024 by Ajay Shrihari, a robotics and AI researcher, and Aniket Mohanty, who has a background in medical image processing.

In under a year of commercial operation, Coral has reached multiple millions in annual revenue and is targeting 4x growth before the end of 2026.

The 💜 of EU tech

The latest rumblings from the EU tech scene, a story from our wise ol’ founder Boris, and some questionable AI art. It’s free, every week, in your inbox. Sign up now!

The problem Coral is solving is not technological complexity, it is administrative volume. In American healthcare, every appointment generates a trail of prior authorisation requests, referral packets, insurance eligibility checks, and discharge paperwork.

Much of this flows through fax machines, which remain deeply embedded in clinical workflows despite being a technology from a previous era.

Rather than attempting to replace fax infrastructure, an approach that would require providers to rebuild systems they cannot afford to rebuild, Coral connects to existing EHR systems, fax lines, and payer portals and automates around them.

Providers do not change how they work. Coral changes what happens inside that workflow.

The company began in the durable medical equipment sector, one of the most fax-intensive corners of outpatient care, where a single order can require multiple rounds of documentation before approval.

DASCO, a home medical equipment provider, has been an early customer, describing turnaround times dropping from hours or days to minutes.

Coral then extended the same model into infusion centres, where a delayed authorisation means a missed dose, not a delayed appointment, and into specialty pharmacy.

In each new vertical, the same administrative bottleneck appeared in the same shape.
The product’s core capability is document understanding at healthcare’s specific level of messiness: handwritten fax forms, scanned insurance cards, prior authorisation templates, and payer portal screens.

Coral’s models have reached 99.7% accuracy across these document types, a threshold the company describes as the minimum viable standard for healthcare, where errors have clinical and financial consequences.

Complete patient intakes, including complex cases, now run in under five minutes. When information is missing, which is frequent in this environment, the platform coordinates with payers, patients, and referral sources to resolve the gap without requiring staff intervention.

The strongest signal in the commercial story is not the revenue figure but the payment behaviour. A portion of Coral’s customers are paying the full contract value upfront, an unusual dynamic in enterprise software, and a striking one in a sector where vendor evaluation cycles are typically slow and risk-averse.

The explanation is mechanical: when a workflow that previously took hours completes in under five minutes at high accuracy, the return on investment is immediate and visible. Commit now, stop the queue now.

Coral recently shipped AI-powered voice and text workflows that automate follow-ups with payers, patients, and referral sources, replacing calls that previously required a staff member to pick up the phone.

The next phase of product development includes an AI workflow builder that will let providers design and deploy their own administrative processes without involving IT, and a co-pilot layer that surfaces operational intelligence from the data already flowing through the platform: which payers have the highest denial rates and why, where cases are stalling in the authorisation process, which referral sources convert reliably and which do not, and what changes would improve outcomes on insurance claim resubmissions.

Rohil Bagga, investor at Lightspeed, described the company as “delivering real outcomes at scale” in an environment where legacy automation has historically failed.

Ashwin KP, investor at Z47, framed the investment thesis around the specific characteristics of healthcare administration: over a trillion dollars in annual overhead, chronically underserved by technology, and requiring deep vertical expertise to crack.

The Series A funds team growth and product development, with Coral adding engineering talent alongside people who have spent careers inside healthcare operations.



Source link

Leave a Reply

Subscribe to Our Newsletter

Get our latest articles delivered straight to your inbox. No spam, we promise.

Recent Reviews


As I’m writing this, NVIDIA is the largest company in the world, with a market cap exceeding $4 trillion. Team Green is now the leader among the Magnificent Seven of the tech world, having surpassed them all in just a few short years.

The company has managed to reach these incredible heights with smart planning and by making the right moves for decades, the latest being the decision to sell shovels during the AI gold rush. Considering the current hardware landscape, there’s simply no reason for NVIDIA to rush a new gaming GPU generation for at least a few years. Here’s why.

Scarcity has become the new normal

Not even Nvidia is powerful enough to overcome market constraints

Global memory shortages have been a reality since late 2025, and they aren’t just affecting RAM and storage manufacturers. Rather, this impacts every company making any product that contains memory or storage—including graphics cards.

Since NVIDIA sells GPU and memory bundles to its partners, which they then solder onto PCBs and add cooling to create full-blown graphics cards, this means that NVIDIA doesn’t just have to battle other tech giants to secure a chunk of TSMC’s limited production capacity to produce its GPU chips. It also has to procure massive amounts of GPU memory, which has never been harder or more expensive to obtain.

While a company as large as NVIDIA certainly has long-term contracts that guarantee stable memory prices, those contracts aren’t going to last forever. The company has likely had to sign new ones, considering the GPU price surge that began at the beginning of 2026, with gaming graphics cards still being overpriced.

With GPU memory costing more than ever, NVIDIA has little reason to rush a new gaming GPU generation, because its gaming earnings are just a drop in the bucket compared to its total earnings.

NVIDIA is an AI company now

Gaming GPUs are taking a back seat

A graph showing NVIDIA revenue breakdown in the last few years. Credit: appeconomyinsights.com

NVIDIA’s gaming division had been its golden goose for decades, but come 2022, the company’s data center and AI division’s revenue started to balloon dramatically. By the beginning of fiscal year 2023, data center and AI revenue had surpassed that of the gaming division.

In fiscal year 2026 (which began on July 1, 2025, and ends on June 30, 2026), NVIDIA’s gaming revenue has contributed less than 8% of the company’s total earnings so far. On the other hand, the data center division has made almost 90% of NVIDIA’s total revenue in fiscal year 2026. What I’m trying to say is that NVIDIA is no longer a gaming company—it’s all about AI now.

Considering that we’re in the middle of the biggest memory shortage in history, and that its AI GPUs rake in almost ten times the revenue of gaming GPUs, there’s little reason for NVIDIA to funnel exorbitantly priced memory toward gaming GPUs. It’s much more profitable to put every memory chip they can get their hands on into AI GPU racks and continue receiving mountains of cash by selling them to AI behemoths.

The RTX 50 Super GPUs might never get released

A sign of times to come

NVIDIA’s RTX 50 Super series was supposed to increase memory capacity of its most popular gaming GPUs. The 16GB RTX 5080 was to be superseded by a 24GB RTX 5080 Super; the same fate would await the 16GB RTX 5070 Ti, while the 18GB RTX 5070 Super was to replace its 12GB non-Super sibling. But according to recent reports, NVIDIA has put it on ice.

The RTX 50 Super launch had been slated for this year’s CES in January, but after missing the show, it now looks like NVIDIA has delayed the lineup indefinitely. According to a recent report, NVIDIA doesn’t plan to launch a single new gaming GPU in 2026. Worse still, the RTX 60 series, which had been expected to debut sometime in 2027, has also been delayed.

A report by The Information (via Tom’s Hardware) states that NVIDIA had finalized the design and specs of its RTX 50 Super refresh, but the RAM-pocalypse threw a wrench into the works, forcing the company to “deprioritize RTX 50 Super production.” In other words, it’s exactly what I said a few paragraphs ago: selling enterprise GPU racks to AI companies is far more lucrative than selling comparatively cheaper GPUs to gamers, especially now that memory prices have been skyrocketing.

Before putting the RTX 50 series on ice, NVIDIA had already slashed its gaming GPU supply by about a fifth and started prioritizing models with less VRAM, like the 8GB versions of the RTX 5060 and RTX 5060 Ti, so this news isn’t that surprising.

So when can we expect RTX 60 GPUs?

Late 2028-ish?

A GPU with a pile of money around it. Credit: Lucas Gouveia / How-To Geek

The good news is that the RTX 60 series is definitely in the pipeline, and we will see it sooner or later. The bad news is that its release date is up in the air, and it’s best not to even think about pricing. The word on the street around CES 2026 was that NVIDIA would release the RTX 60 series in mid-2027, give or take a few months. But as of this writing, it’s increasingly likely we won’t see RTX 60 GPUs until 2028.

If you’ve been following the discussion around memory shortages, this won’t be surprising. In late 2025, the prognosis was that we wouldn’t see the end of the RAM-pocalypse until 2027, maybe 2028. But a recent statement by SK Hynix chairman (the company is one of the world’s three largest memory manufacturers) warns that the global memory shortage may last well into 2030.

If that turns out to be true, and if the global AI data center boom doesn’t slow down in the next few years, I wouldn’t be surprised if NVIDIA delays the RTX 60 GPUs as long as possible. There’s a good chance we won’t see them until the second half of 2028, and I wouldn’t be surprised if they miss that window as well if memory supply doesn’t recover by then. Data center GPUs are simply too profitable for NVIDIA to reserve a meaningful portion of memory for gaming graphics cards as long as shortages persist.


At least current-gen gaming GPUs are still a great option for any PC gamer

If there is a silver lining here, it is that current-gen gaming GPUs (NVIDIA RTX 50 and AMD Radeon RX 90) are still more than powerful enough for any current AAA title. Considering that Sony is reportedly delaying the PlayStation 6 and that global PC shipments are projected to see a sharp, double-digit decline in 2026, game developers have little incentive to push requirements beyond what current hardware can handle.

DLSS 5, on the other hand, may be the future of gaming, but no one likes it, and it will take a few years (and likely the arrival of the RTX 60 lineup) for it to mature and become usable on anything that’s not a heckin’ RTX 5090.

If you’re open to buying used GPUs, even last-gen gaming graphics cards offer tons of performance and are able to rein in any AAA game you throw at them. While we likely won’t get a new gaming GPU from NVIDIA for at least a few years, at least the ones we’ve got are great today and will continue to chew through any game for the foreseeable future.



Source link